We believe that patients need to participate in all conversations that relate to access to treatment, safety, or the quality of their care. At GHLF Australia, we raise the voice of people with chronic health conditions, carers and their community by focusing on various advocacy priorities at the community, state and federal level.
GHLF Australia regularly works with physician networks, national and state-level professional societies and other not-for-profit organisations and patient support groups to maximise the volume of our shared messages. This collaborative advocacy allows GHLF Australia to leverage the reach and impact of healthy living messages to effectively overcome barriers to care.
You can contribute to our advocacy efforts by responding to one of our surveys, becoming a GHLF Australia member or joining our Patient Community Council.
Global Healthy Living Foundation Australia submission for the National Medicines Policy Review
Global Healthy Living Foundation Australia submission for the Consultation Draft of the Primary Health Care 10 Year Plan.
GHLF Australia/CreakyJoints Australia submission for Updating the Guiding Principles to Achieve Continuity in Medication Management
GHLF Australia comments to the Pharmaceutical Benefits Advisory Committee about the inclusion of Vaxelis (hexavalent) on the PBS
CreakyJoints Australia submission for the Parliamentary Inquiry into Childhood Rheumatic Diseases
GHLF Australia/CreakyJoints Australia submission for the ANAO Audit of Australia’s COVID-19 Vaccination Rollout
GHLF Australia/CreakyJoints Australia submission to support the listing of Deucravacitinib (Sotyktu®) on the PBS for the treatment of severe chronic plaque psoriasis
GHLF Australia and CreakyJoints Australia submission for the Revised 2022 National Medicines Policy
GHLF Australia and CreakyJoints Australia submission to support the listing of tofacitinib (Xeljanz®) on the PBS for the treatment of juvenile idiopathic arthritis
GHLF Australia and CreakyJoints Australia submission to support the listing of Romosozumab (Evenity®) on the PBS for
the treatment of osteoporosis